

# Pilot study rectifies real-world study design to support regulatory decision making

Atheline Major-Pedersen<sup>1</sup>, Jens Aberle<sup>2</sup>, Paolo Sbraccia<sup>3</sup>, Naveen Rathor<sup>1</sup>, and Anne Helene Olsen<sup>1</sup>

<sup>1</sup>Novo Nordisk A/S

<sup>2</sup>Universitäres Adipositas Centrum

<sup>3</sup>University Tor Vergata

December 2, 2022

## Abstract

**Purpose:** To evaluate the feasibility of a drug utilization study (DUS) investigating real-world use of Saxenda<sup>®</sup> and Victoza<sup>®</sup> in Europe. Economic and time constraints may incite researchers to avoid formalized pilot studies. Here, we report results of a pilot study which rectified the ensuing DUS protocol, thus ascertaining fit-for-purpose data availability and quality, and supporting regulatory decision making. **Methods:** A retrospective multicenter medical chart review in Germany and Italy, 6 months after Saxenda<sup>®</sup> (liraglutide 3.0 mg, a once-daily human glucagon-like peptide-1 analog for weight management) launch, ahead of a full DUS. Collected data included: site characteristics, patient demographics, medical history, drug utilization (e.g., brand, dose, indication, weight-related comorbidities). Target study population: 100 initiators (25 Saxenda<sup>®</sup> and 25 Victoza<sup>®</sup> initiators in both Germany and Italy). Informed consent was obtained before medical-chart data extraction. **Results:** Overall, 218 sites were contacted. Fifteen sites (nine in Italy; six in Germany) enrolled initiators. There were 39 Saxenda<sup>®</sup> initiators (33 in Italy; six in Germany) and 52 Victoza<sup>®</sup> initiators (31 in Italy; 21 in Germany). Data were available for all Saxenda<sup>®</sup> initiators and all Victoza<sup>®</sup> initiators in Italy, and for 12 of 21 Victoza<sup>®</sup> initiators in Germany. In nine of the 12 initiators, only target dose was recorded, with no current dose provided. **Conclusions:** The pilot study indicated a poor enrollment feasibility of Saxenda<sup>®</sup> initiators in Germany and an unfit-for-purpose dose-related data quality. Based on these findings, refinements were implemented to the ensuing DUS protocol, thus ensuring robust real-world data to support regulatory decision making.

## Hosted file

pds-22-0500-File001.docx available at <https://authorea.com/users/562124/articles/609381-pilot-study-rectifies-real-world-study-design-to-support-regulatory-decision-making>

## Hosted file

pds-22-0500-File002.docx available at <https://authorea.com/users/562124/articles/609381-pilot-study-rectifies-real-world-study-design-to-support-regulatory-decision-making>

## Hosted file

pds-22-0500-File003.docx available at <https://authorea.com/users/562124/articles/609381-pilot-study-rectifies-real-world-study-design-to-support-regulatory-decision-making>